31 / 34
Page 68
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
16
th
EuroSciCon Conference on
Immunology
M a r c h 1 1 - 1 2 , 2 0 1 9
Am s t e r d a m , N e t h e r l a n d s
Immunology 2019
B
ifunctional peptide inhibitors (BPI) are conjugates between antigenic peptides and cell adhesion peptides or protein. The
hypothesis is that BPI molecules simultaneously bind to MHC-II and ICAM-1 on antigen-presenting cells (APC) to inhibit the
formation of the immuno¬logical synapse at the interface between T cells and APC followed. Therefore, this inhibition induces
selective alteration of T-cell differentiation from inflammatory to regulatory responses. Our results showed that BPI molecules
suppressed experimental autoimmune encephalomyelitis (EAE) disease in mice significantly better than antigenic peptide
(i.e., PLP peptide) or PBS. BPI molecules have been shown to suppress rheumatoid arthritis in collagen-induced arthritis mice
significantly better than antigenic peptide (i.e., Collagen-II peptide) or PBS. In EAE mice, BPI molecules suppressed the production
of inflammatory cytokines and induced the production of regulatory and/or suppressor cytokines. We have also shown that BPI
molecules suppressed EAE in antigen specific manner. Currently, we are working on understanding the mechanisms of action of
BPI molecules in suppressing autoimmune diseases in animal models.
Siahaan@ku.eduuBifunctional peptide inhibitors for controlling
autoimmune diseases
Teruna J Siahaan
The University of Kansas, USA
J Clin Immunol Allergy 2019, Volume:5
DOI: 10.21767/2471-304X-C1-009